Relief Therapeutics Holding SA
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
Relief Therapeutics Holding SA (RLFTF) - Net Assets
Latest net assets as of June 2025: $32.63 Million USD
Based on the latest financial reports, Relief Therapeutics Holding SA (RLFTF) has net assets worth $32.63 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.99 Million) and total liabilities ($15.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $32.63 Million |
| % of Total Assets | 68.0% |
| Annual Growth Rate | 6.45% |
| 5-Year Change | -45.31% |
| 10-Year Change | N/A |
| Growth Volatility | 138.22 |
Relief Therapeutics Holding SA - Net Assets Trend (2016–2024)
This chart illustrates how Relief Therapeutics Holding SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Relief Therapeutics Holding SA (2016–2024)
The table below shows the annual net assets of Relief Therapeutics Holding SA from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $36.66 Million | -29.80% |
| 2023-12-31 | $52.23 Million | -64.08% |
| 2022-12-31 | $145.42 Million | -19.89% |
| 2021-12-31 | $181.53 Million | +170.77% |
| 2020-12-31 | $67.04 Million | +368.90% |
| 2019-12-31 | $14.30 Million | -32.82% |
| 2018-12-31 | $21.28 Million | +1.61% |
| 2017-12-31 | $20.95 Million | -5.81% |
| 2016-12-31 | $22.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Relief Therapeutics Holding SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21791700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $272.41 Million | 742.98% |
| Total Equity | $36.66 Million | 100.00% |
Relief Therapeutics Holding SA Competitors by Market Cap
The table below lists competitors of Relief Therapeutics Holding SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Delek Automotive Systems Ltd
TA:DLEA
|
$7.31 Million |
|
Heng Huat Resources Group Bhd
KLSE:0175
|
$7.31 Million |
|
LETUS CAPITAL ZY 1
F:7I4
|
$7.32 Million |
|
Sundance Strategies Inc
OTCQB:SUND
|
$7.32 Million |
|
Zacatecas Silver Corp
PINK:ZCTSF
|
$7.30 Million |
|
DAVIDsTEA Inc.
PINK:DTEAF
|
$7.30 Million |
|
Vertex Resource Group Ltd
V:VTX
|
$7.30 Million |
|
NuEnergy Gas Limited
F:NUB
|
$7.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relief Therapeutics Holding SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 52,228,000 to 36,664,000, a change of -15,564,000 (-29.8%).
- Net loss of 17,119,000 reduced equity.
- Other factors increased equity by 1,555,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.12 Million | -46.69% |
| Other Changes | $1.55 Million | +4.24% |
| Total Change | $- | -29.80% |
Book Value vs Market Value Analysis
This analysis compares Relief Therapeutics Holding SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 215.56x to 0.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.01 | $2.25 | x |
| 2018-12-31 | $0.01 | $2.25 | x |
| 2019-12-31 | $0.01 | $2.25 | x |
| 2020-12-31 | $0.02 | $2.25 | x |
| 2021-12-31 | $0.04 | $2.25 | x |
| 2022-12-31 | $0.03 | $2.25 | x |
| 2023-12-31 | $4.16 | $2.25 | x |
| 2024-12-31 | $2.92 | $2.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relief Therapeutics Holding SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.39%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.45x
- Recent ROE (-46.69%) is above the historical average (-49.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -75.71% | -112226.67% | 0.00x | 1.41x | $-19.06 Million |
| 2017 | -13.78% | 0.00% | 0.00x | 1.48x | $-4.98 Million |
| 2018 | -2.05% | -77.17% | 0.02x | 1.67x | $-2.56 Million |
| 2019 | -52.18% | 0.00% | 0.00x | 1.39x | $-8.89 Million |
| 2020 | -11.68% | 0.00% | 0.00x | 1.16x | $-14.53 Million |
| 2021 | -19.12% | -1045.02% | 0.01x | 1.39x | $-52.86 Million |
| 2022 | -34.93% | -835.22% | 0.03x | 1.30x | $-65.33 Million |
| 2023 | -187.99% | -1627.40% | 0.08x | 1.46x | $-103.40 Million |
| 2024 | -46.69% | -203.39% | 0.16x | 1.45x | $-20.79 Million |
Industry Comparison
This section compares Relief Therapeutics Holding SA's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relief Therapeutics Holding SA (RLFTF) | $32.63 Million | -75.71% | 0.47x | $7.30 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |